Overall survival ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
Summary of findings: Ursodeoxycholic acid showed no clear difference in overall survival ( compared with placebo or no treatment (low certainty).
1 finding from 1 review
Overall survival ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease
Summary of findings: Defibrotide showed no clear difference in overall survival ( compared with no treatment (low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease
Summary of findings: Defibrotide showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease
Summary of findings: Defibrotide showed no clear difference in mortality attributable to hepatic veno‐occlusive disease ( compared with no treatment (low certainty).
1 finding from 1 review
Quality of life · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease
It is very uncertain whether summary of findings: Defibrotide changes frequency of adverse events ( compared with no treatment (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with haematological malignancies
It is very uncertain whether summary of findings: Glutamine changes incidence of hepatic veno‐occlusive disease ( compared with placebo (very low certainty).
1 finding from 1 review
Overall survival · People undergoing stem cell transplant with haematological malignancies
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with haematological malignancies
It is very uncertain whether summary of findings: Glutamine changes all‐cause mortality at 100 days post‐transplant ( compared with placebo (very low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with haematological malignancies
It is very uncertain whether summary of findings: Glutamine changes mortality attributable to hepatic veno‐occlusive disease ( compared with placebo (very low certainty).
1 finding from 1 review
Quality of life · People undergoing stem cell transplant with haematological malignancies
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
Summary of findings: Ursodeoxycholic acid may leads to lower all‐cause mortality at 100 days post‐transplant ( compared with placebo or no treatment (low certainty).
1 finding from 1 review
Frequency of adverse events ( · People undergoing stem cell transplant with haematological malignancies
It is very uncertain whether summary of findings: Glutamine changes frequency of adverse events ( compared with placebo (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Fresh frozen plasma changes incidence of hepatic veno‐occlusive disease ( compared with no treatment (very low certainty).
1 finding from 1 review
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Antithrombin III plus heparin changes incidence of hepatic veno‐occlusive disease ( compared with heparin alone (very low certainty).
1 finding from 1 review